Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
SNDX
SNDX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SNDX News
Revumenib Shows Promising Clinical Data in Acute Leukemia
Jun 11 2026
Newsfilter
Syndax Pharmaceuticals Issues $250M Convertible Senior Notes
Jun 04 2026
seekingalpha
Syndax Releases Revuforj Data for Acute Leukemia Treatment
Jun 03 2026
NASDAQ.COM
Syndax's Revuforj Showcases New Data at ASCO Meeting
May 21 2026
Newsfilter
Revumenib Shows Promising Results in Acute Leukemia Treatment
May 12 2026
Newsfilter
Syndax Pharmaceuticals Q1 2026 Earnings Call Highlights
May 01 2026
seekingalpha
Syndax Pharmaceuticals Q1 Earnings Beat Expectations
Apr 30 2026
seekingalpha
Syndax Pharmaceuticals to Report Q1 2026 Financial Results
Apr 24 2026
Newsfilter
DAFNA Capital Reduces Stake in Syndax Pharmaceuticals
Mar 22 2026
Fool
DAFNA Capital Management Reduces SNDX Holdings
Mar 22 2026
NASDAQ.COM
Kynam Capital Management Reduces Syndax Holdings
Mar 21 2026
Fool
Kynam Capital Reduces Syndax Stake
Mar 21 2026
NASDAQ.COM
Kynam Capital Management Cuts Viridian Stake by Over $81 Million
Mar 21 2026
Yahoo Finance
Kynam Capital Reduces Stake in Cogent Biosciences by $48 Million
Mar 21 2026
Yahoo Finance
Sphera Increases Stake in Syndax Pharmaceuticals
Mar 13 2026
Fool
Sphera Funds Increases Stake in Syndax Pharmaceuticals
Mar 13 2026
NASDAQ.COM
Show More News
